-
LATEST NEWS
more news
- Adamis Pharmaceuticals CEO Provides Update for ShareholdersPR Newswire(Fri, May 3, 2013)
- ADAMIS PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct FinaEDGAR Online(Mon, Apr 8)
- ADAMIS PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements andEDGAR Online(Tue, Mar 19)
- European Exposure Slows Down Large Medical Device Companies; Holding Smaller Names May Result in More Upside When Investing in This Healthcare Segment, According to Expert Equity AnalystWall Street Transcript(Mon, Mar 18)
- ADAMIS PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or PrEDGAR Online(Tue, Mar 12)
- ADAMIS PHARMACEUTICALS CORP Files SEC form 8-K, Other EventsEDGAR Online(Fri, Mar 1)
- Adamis Pharmaceuticals Prevails in License Dispute LitigationPR Newswire(Thu, Feb 28)
- ADAMIS PHARMACEUTICALS CORP FinancialsEDGAR Online Financials(Sat, Feb 23)
- ADAMIS PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, Feb 19)
- ADAMIS PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Wed, Jan 30)
- ADAMIS PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct FinaEDGAR Online(Fri, Jan 4)
- ADAMIS PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, Nov 13)
- ADAMIS PHARMACEUTICALS CORP Files SEC form 8-K, Other EventsEDGAR Online(Tue, Oct 30)
- ADAMIS PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Submission of Matters toEDGAR Online(Fri, Oct 12)
- ADAMIS PHARMACEUTICALS CORP Files SEC form 10-Q/A, Quarterly ReportEDGAR Online(Fri, Aug 17)
-
Welcome to Adamis Pharmaceuticals
Adamis Pharmaceuticals is a commercial-stage specialty pharmaceutical company with products concentrated in three major areas: Allergy/Respiratory, Oncology and Immunology/Infectious Diseases.
NEW YORK, NY (October 26, 2011)...Crystal Research Associates, LLC
announced today that it has issued an Executive Informational Overview® (EIO®)
on Adamis Pharmaceuticals Corp. (ADMP-OTCBB).
The full 52-page report by Jeffrey J. Kraws can be seen here
Adamis Pharmaceuticals Product Pipeline
